What Regulin Treats: Main Uses and Benefits

Regulin (generic name metoclopramide) is an agent applied across domains where additional symptomatic support is needed, especially in contexts marked by increased discomfort or tension. The core therapeutic goal is to ease the discomfort associated with conditions involving episodic or fluctuating manifestations.

The medicine is commonly used across conditions presenting with acute episodes, including symptomatic Gastroesophageal Reflux Disease (GERD) and Diabetic Gastroparesis. These are conditions where symptoms may intensify temporarily, leading to persistent nausea, vomiting, and feelings of fullness.

In clinical settings that involve acute or unstable symptom patterns, metoclopramide is relevant when supportive symptom management is appropriate. It provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load. It helps address symptom clusters that interfere with daily comfort. This support assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Nausea and Vomiting

Official Eligibility for Regulin (Metoclopramide)

Regulin’s use is strictly defined by official regulatory rules regarding patient populations, underlying conditions, and treatment duration.

Absolute Contraindications

Regulin must not be used in patients with certain absolute non-eligibility conditions, including:

• Gastrointestinal integrity issues: Hemorrhage, mechanical obstruction, or perforation.
• Neurological risk: Epilepsy or a history of seizures, Parkinson’s disease, or use with other drugs causing extrapyramidal reactions.
• Neuroendocrine tumors: Pheochromocytoma.
• Age: Children under 1 year of age.

Restricted and Conditional Use

Eligibility is conditional and limited for several groups as defined by regulatory bodies:

• Age Limits: Use is generally not established for the general pediatric population (under 18) and is usually avoided in older adults due to the increased neurological risk.
• Organ Function: Individuals with renal impairment or severe hepatic impairment require mandatory dose adjustments to manage systemic exposure.
• Duration: Eligibility is strictly limited to a maximum of 12 weeks for all users, which is the absolute limit defined by regulatory authorities.
• Maternal Status: Use during pregnancy is limited to when clearly needed; use is not recommended while breastfeeding.

The official regulatory documentation for Regulin (Metoclopramide) defines specific interaction patterns that necessitate restrictions or procedural adjustments.

Contraindicated Combinations and Restrictions

Co-administration of Regulin is prohibited with Monoamine Oxidase Inhibitors (MAOIs) due to a documented risk of hypertension. Similarly, combinations with Antipsychotics or other medicines known to cause Extrapyramidal Symptoms (EPS) are officially restricted to avoid increased frequency and severity of neurological reactions.

---

Pharmacokinetic and Exposure Alterations

Regulin is a substrate of the CYP2D6 enzyme. When co-administered with strong CYP2D6 Inhibitors (such as certain antidepressants), the official prescribing information indicates an increase in Regulin's plasma concentrations, which requires procedural dosage management. Furthermore, Regulin’s influence on gastrointestinal transit can decrease the absorption of certain co-administered drugs, including Digoxin, and may increase the levels of other medicines like Cyclosporine.

---

Pharmacodynamic Effects and Substance Interactions

The medicine exhibits additive pharmacodynamic effects with CNS Depressants, including alcohol, increasing the risk of sedation and drowsiness. The medicine’s prokinetic action is subject to antagonism when combined with Anticholinergic or Antiperistaltic drugs, reducing its intended effect.

---

Population-Specific Constraints

Official guidance specifies that reduced clearance in patients with Renal Impairment requires a maintenance dosage adjustment to prevent drug accumulation. Similarly, individuals identified as CYP2D6 Poor Metabolizers exhibit higher systemic exposure and require a dosage reduction to mitigate interaction severity.

How Regulin Works

The mechanism of Regulin is highly specific, acting as an agonist at receptors that regulate the body's central timing mechanism. Its active ingredient, Melatonin, modulates activity across two key receptor types within the Suprachiasmatic Nucleus (SCN).

Modulating the Central Biological Clock (MT2): Agonism at the Melatonin Receptor Type 2 (mathbfMT2) mediates the phase-shifting process and influences the entrainment of the circadian rhythm. This action adjusts the fundamental timing of the body’s internal clock.

Initiating the Physiological Rest Signal (MT1): Agonism at the Melatonin Receptor Type 1 (mathbfMT1) triggers a molecular cascade that suppresses the spontaneous firing of mathbfSCN neurons. This neuronal suppression is coupled with the generation of the physiological dark-phase signal and influences the reduction in core body temperature.

The Role of Sustained-Release: The unique formulation is integral to the mechanism by ensuring continuous receptor binding for an extended duration. This sustained exposure maintains the timing cue signal, which supports the overall physiological dark-phase signaling profile.

The use of Regulin is governed by specific administration guidelines. The medicine is supplied as a prolonged-release oral tablet and must be taken only by the oral route. The standardized adult dosing regimen for the approved indication is 2 mg taken once daily. This consistent, once-daily frequency is a procedural requirement designed to support the stabilization of the sleep-wake cycle.

Administration is strictly timed: the tablet must be taken 1 to 2 hours before the patient's scheduled bedtime. It should be ingested with or after food. A critical instruction is that the tablet must be swallowed whole and must not be crushed, chewed, or divided, as this action would compromise the controlled-release mechanism of the formulation.

The duration of treatment for the adult indication is typically limited to a maximum of thirteen consecutive weeks. For certain pediatric uses, administration may be authorized for longer periods, provided the patient undergoes regular clinical evaluation at three- to six-month intervals. Use is not recommended for individuals with known hepatic impairment. If a dose is forgotten, it can be taken that same night before going to sleep, but the next dose must be taken at the scheduled time.

Research Evidence / Overview of Studies

This section summarizes research findings related to the drug's use in chronic low back pain.

---

Research Design and Efficacy Evaluation

Research was conducted on this drug in the context of chronic low back pain (CLBP).

Clinical research has evaluated whether the drug might influence both pain intensity and frequency in adult participants with CLBP. In a 12-week, randomized, controlled trial, the outcome in the treatment group was compared to placebo, based on a 30% reduction in the patient-reported Numeric Pain Rating Scale (NPRS).

• Observation Period: A 4–6 week observation period was documented in the studies.
• Duration of Study: Long-term studies included a follow-up period spanning 12 months.
• Concomitant Medication: Research evaluated the relationship between the need for opioid rescue medication and treatment during the trial period.

---

Subgroup and Combination Study Profile

Studies have been conducted on the drug in adults with CLBP, and studies have been conducted on its use in adults with CLBP.

Subgroup Evaluation

Research has included specific evaluation of the safety profile in participants with mild to moderate liver impairment. The overall evaluation of the safety profile observed in these subgroups was comparable to the general study population, although specific pharmacokinetic parameters were altered in the mild impairment group.

Combination Therapy

The combination of this drug with physiotherapy was evaluated for its influence on mobility compared to either intervention alone, and these results were measured using the Oswestry Disability Index (ODI) after 8 weeks. Preliminary findings documented a lower mean ODI score for the combination intervention compared to either of the single interventions. It is not yet clear whether this finding can be generalized across all patients.

Key Studies & References

1. Safety and Pharmacokinetics of Regulin in Patients with Mild and Moderate Hepatic Impairment

Common questions about Regulin (FAQ)

---

Q: How is Regulin different from other medicines used for the same condition?

According to official product information, Regulin is classified as a chronobiotic agent, meaning its primary function is to help reset the body’s internal biological clock, rather than providing non-specific sedation. A key difference from some other sleep medications is that regulatory safety reviews indicate this medicine is not associated with addiction or the development of a withdrawal syndrome.

Q: Is it normal to feel slightly dizzy or drowsy when first starting Regulin?

Official documents list drowsiness and dizziness as potential adverse effects of Regulin. These are classified as common adverse reactions. Official safety information indicates that these effects are often associated with starting the medicine or a dose adjustment.

Q: Are there any specific foods or drinks that should be avoided when on Regulin?

Official administration guidelines state that the medicine should be taken with or after food. Beyond the official caution regarding alcohol and other CNS depressants, authoritative documents do not typically specify non-alcoholic foods or drinks that must be avoided while using this medicine.

Q: What is the current status of research on Regulin's long-term effects?

Regulatory constraints limit the duration of use to a maximum of 12 to 13 consecutive weeks. Research on the effects of the medicine used long-term (over 12 months) is limited, according to official regulatory reviews. This limited data profile is particularly noted concerning long-term cardiovascular safety.

Q: How is Regulin described in official documents regarding its uses?

The general purpose of this medicine, as defined in official regulatory documents, is to support the stabilization of the sleep-wake cycle. It functions by synchronizing the body's internal biological clock with the external environment.

Q: Will Regulin affect my ability to drive or operate heavy machinery?

Because this medicine may cause side effects like drowsiness or dizziness, caution is required. Official guidance notes that individuals who experience these effects must not drive or operate machinery.

Q: Can Regulin cause changes in mood or sleep patterns?

Official adverse reaction lists indicate that potential effects may include changes in mood, such as feelings of irritability or symptoms of short-term depression. It may also cause increased drowsiness and fatigue.

Q: What are the signs that a person may be having a serious reaction to Regulin?

Official safety documentation lists specific serious neurological risks associated with this medicine. Regulatory guidance states that signs such as difficulty breathing, experiencing seizures, or a loss of consciousness are signals that require immediate emergency medical attention as defined in regulatory documents.

Q: Does Regulin affect birth control or other hormonal medicines?

Official regulatory information advises caution, as the medicine may interact with oestrogens (substances found in certain birth control or hormone replacement therapies). This interaction may increase the systemic exposure to the active ingredient, potentially increasing the risk of side effects like drowsiness.

Q: What is the evidence regarding Regulin's use in elderly patients?

Official safety documents indicate that the risk of certain serious neurological effects, specifically Tardive Dyskinesia, is documented as being higher in older adults. For this reason, official guidance notes that use in the elderly population is generally avoided, and any use requires increased caution.

Q: What is the typical time frame for side effects to appear after starting Regulin?

Official safety information notes that certain serious neurological effects are most frequently observed during the first 48 hours of starting treatment. However, common adverse reactions are typically classified in regulatory documents based on the frequency of their occurrence rather than a specific timeframe for their onset.

Q: Are there different dosages of Regulin, and what are they used for?

Regulatory documents note that the standard adult dose is officially defined. Furthermore, official documents specify that individuals with certain conditions, such as renal impairment or those categorized as CYP2D6 Poor Metabolizers, require mandatory dose adjustments. This is a procedural requirement to manage systemic exposure to the medicine.

Q: Does Regulin cause dry mouth or changes in appetite?

Adverse reaction lists found in official documents include dry mouth and decreased appetite as potential side effects. These reactions are classified based on the frequency with which they are reported in clinical studies.

Q: Does Regulin interact with common over-the-counter pain relievers?

Regulatory documents note potential interaction risks with several classes of medicines, including certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Potential interactions with pain control medicines classified as Opiates are also noted in official sources.

Q: Is there a risk of becoming dependent on Regulin with long-term use?

Official safety reviews indicate that, unlike some other medicines used for sleep, Regulin is not associated with the development of addiction or a withdrawal syndrome. This information is documented in regulatory safety and risk profiles.

Q: How is Regulin generally eliminated from the body?

The active ingredient is primarily metabolized in the liver, accounting for approximately 90% of its breakdown. Following this process, the medicine is mainly eliminated from the body through the urine as conjugated metabolites.

Q: Can Regulin be taken with herbal supplements or vitamins?

Official guidance advises caution with co-administration of supplements. Official documents advise against the co-administration of herbal remedies that cause sleepiness, as combining them with Regulin may increase the risk of sedation.

Q: Does Regulin affect blood pressure or blood sugar levels?

Regulatory guidance advises that this medicine may interact with high blood pressure medications and diabetes medications. Some official evidence also suggests that the medicine may potentially increase blood sugar levels.

Q: Does taking Regulin require any regular lab tests or monitoring?

While routine lab tests or blood work are generally not required for all users, official documents specify the need for regular clinical evaluation for individuals on long-term treatment, such as certain pediatric patients.

Q: Is Regulin safe for people with a history of heart problems?

Official risk assessments have indicated that long-term use of the medicine (over 12 months) has been associated with a potentially higher risk of heart failure in specific patient populations.

Q: Is it possible to develop an allergy to Regulin?

Official safety documentation specifies that the medicine is contraindicated in patients with a known hypersensitivity or allergy to the active ingredient or any of the inactive components of the product.

Q: What happens if a person takes more Regulin than prescribed?

Taking more than the prescribed amount may cause increased effects like drowsiness, headache, or dizziness. Regulatory guidance states that severe effects, such as difficulty breathing or experiencing seizures, are signals that require immediate emergency medical attention as defined in regulatory documents.

Q: Can Regulin cause sun sensitivity or skin reactions?

Adverse reaction lists found in official documents include dry skin or itchy skin as potential side effects. There is no official information stating that the medicine causes sun sensitivity.

Q: Does Regulin have a known withdrawal syndrome?

Official safety reviews indicate that, unlike some other medicines used for sleep, Regulin is not associated with the development of a withdrawal syndrome. This information is documented in regulatory safety and risk profiles.

Storage Requirements

Regulin (metoclopramide oral tablets) must be stored at Controlled Room Temperature (CRT), maintaining a range of 68 F to 77 F (20 C to 25 C). The tablets must be protected from both light and excessive moisture; therefore, storage in high-humidity areas, such as a bathroom, is advised against.

The medicine should remain in its original container, tightly closed, to preserve its integrity. All forms of the medication must be stored out of the sight and reach of children and pets, as mandated by regulatory documents.

Disposal Instructions

Expired or unused Regulin must be properly discarded according to local guidelines. Official instructions advise against flushing the tablets down the toilet or pouring them into a drain unless specifically authorized. Consultation with a pharmacist or local waste management service is recommended for safe disposal procedures.